Keywords: wyeth, submits, bla, prevnar, drug, major, pharmaceuticals
Wyeth submits BLA for Prevnar 13
Article | 02 April 2009
US drug major Wyeth Pharmaceuticals has submitted a Biologic License Application to the Food and Drug Administration for Prevnar 13, pneumococcal 13 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
